SCHEDULE: Federated Hermes Discloses 10.31% Stake in Forte Biosciences

Federated Hermes, Inc. and related entities have filed a Schedule 13G, reporting beneficial ownership of 10.31% of Forte Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust, Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, have jointly filed a Schedule 13G.
• This filing indicates beneficial ownership of 2,110,516 shares of Forte Biosciences, Inc. common stock.
• This ownership stake represents 10.31% of the class of securities.
• The filing is an amendment (Amendment No. 3) and the event date requiring the filing is June 30, 2026.
• The reporting persons have disclaimed beneficial ownership of securities held by managed funds, stating the filing should not be construed as an admission of beneficial ownership of those specific securities.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It reports a significant ownership stake but includes strong disclaimers regarding beneficial ownership of managed funds, indicating a standard disclosure rather than a strong positive or negative signal about the company's performance.

Positives

• Significant ownership stake of 10.31% reported by Federated Hermes and associated entities in Forte Biosciences, Inc.

Negatives

• The filing explicitly disclaims beneficial ownership of securities held by managed funds, indicating a complex ownership structure and potential separation of control.

Risks

• The disclaimer of beneficial ownership for managed funds could imply potential future changes in investment strategy or divestment from those specific holdings.
• The joint filing agreement notes that it should not be construed as an admission that the reporting persons constitute a group for purposes of Regulation 13D-G, which could have implications for future regulatory scrutiny or actions.

Future Outlook

No specific forward-looking statements or guidance are provided in this Schedule 13G filing, as it primarily concerns current beneficial ownership.

Management Comments

• In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment advisors accumulating significant stakes in public companies. This filing by Federated Hermes indicates a substantial investment in Forte Biosciences, Inc., positioning them as a key shareholder.

Stakeholder Impact

• Shareholders: The significant stake held by Federated Hermes may influence corporate governance decisions and potentially signal confidence in the company's future, though disclaimers suggest a nuanced relationship.
• Management: May face increased engagement or scrutiny from a large institutional shareholder.
• Creditors: No direct impact indicated by this filing.

Next Steps

• Continued monitoring of Forte Biosciences, Inc. for any further filings or announcements from Federated Hermes, Inc. and associated entities.
• Observation of Forte Biosciences, Inc.'s strategic developments and financial performance to assess the impact of significant institutional ownership.

Key Dates

Keywords

Forte Biosciences, Federated Hermes, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Investment Management, Shareholder